The application of radiomics features for the prediction of Ki67 expression status has been reported in gastrointestinal stromal tumor [10], breast cancer [30], thyroid cancer [31], lung cancer [32], liver cancer [33] and glioma [34]. This evidence concerns the gene MKI67 and breast cancer.